Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Net Margin readings, the most recent being 10.54% for Q1 2026.

  • On a quarterly basis, Net Margin rose 435.0% to 10.54% in Q1 2026 year-over-year; TTM through Mar 2026 was 9.69%, a 1162.0% increase, with the full-year FY2025 number at 8.71%, up 1710.0% from a year prior.
  • Net Margin hit 10.54% in Q1 2026 for Kiniksa Pharmaceuticals International, up from 7.02% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 226.05% in Q3 2022 to a low of 99.56% in Q4 2023.
  • Median Net Margin over the past 5 years was 0.99% (2024), compared with a mean of 1.02%.
  • Biggest five-year swings in Net Margin: skyrocketed 47858bps in 2022 and later crashed -24671bps in 2023.
  • Kiniksa Pharmaceuticals International's Net Margin stood at 61.12% in 2022, then plummeted by -263bps to 99.56% in 2023, then skyrocketed by 99bps to 0.99% in 2024, then skyrocketed by 809bps to 7.02% in 2025, then skyrocketed by 50bps to 10.54% in 2026.
  • The last three reported values for Net Margin were 10.54% (Q1 2026), 7.02% (Q4 2025), and 10.19% (Q3 2025) per Business Quant data.